Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Epigenetics Drugs and Diagnostic Technologies Market is a leading edge in healthcare, which studies and controls how biological events modify epigenetic changes to treat and diagnose many diseases. Epigenetics involves modifications of DNA or its associated proteins that affect gene expression without modifying the underlying genetic code. This market has been growing rapidly because of the increased recognition of the role of epigenetic factors in the development and progression of diseases such as cancer, neurological disorders, and autoimmune conditions. Various drugs and diagnostic technologies exist in this market meant to target and analyze these epigenetic marks.
Epigenetic drugs are essential component parts of this market with novel therapeutic approaches. Epigenetic marks can be modified by drugs such as DNA methyltransferase inhibitors or histone deacetylase inhibitors thus they may reverse abnormal gene expression patterns commonly observed in cancer among other diseases. The demand for more focused therapies that will take care of personal needs keeps on driving the market towards the development of new drugs designed to target only specific pathways related to the field of epigenetics. Such medications have shown potential for treating various illnesses as well as overcoming some challenges found in traditional treatment methods such as drug resistance.
Diagnostic technologies help in identifying or understanding various forms of epigenetic changes occurring within different diseases within Epigenetics Drugs and Diagnostic Technologies Market. For example, by using DNA methylation analysis or chromatin immunoprecipitation sequencing (ChIP-seq), it is possible for researchers or medical practitioners to study profiles about genome-wide location where these modifications occur pertaining to all genes that bear them. These diagnostic tools are used for disease prognosis, diagnosis and when developing personalized treatment plans for patients. In addition, there is a continuous advancement in diagnostic technology with higher resolution power and sensitivity hence enabling detection even small changes caused by epigenomic effects.
Cancer is a major focus area within Epigenetics Drugs & Diagnostic Technologies Market. A significant proportion of cancer cells have aberrant DNA methylation patterns and histone modifications leading to unchecked cell growth and tumor progression. Epigenetic drugs are being designed to target these changes with the aim of normalizing gene expression or suppressing cancer cell proliferation. Diagnostic technologies such as liquid biopsy assays analyzing circulating tumor DNA for epigenetic changes make it possible to detect cancers at early stages and monitor response to treatment.
Another important segment in this market is neurological disorders, including Alzheimer’s disease and Parkinson’s disease. Epigenetic modifications influence genes associated with neurodegenerative conditions. Drugs that target these modifications intend to slow down the disease progression while alleviating its symptoms. On the other hand, diagnostic technologies specific to these diseases help in identifying particular epigenetic signature for different types of neurological disorders thereby facilitating precise diagnosis and potential stratification of treatment.
The Epigenetics Drugs & Diagnostic Technologies Market has tremendous potential but also faces challenges such as the complexity of epigenetic regulation, robust validation of diagnostic markers, and ethical considerations tied to epigenetic interventions. Many distinct types of epigenetic mechanisms are involved in an intricate interplay that makes it difficult for one to formulate directed drugs. Furthermore, ensuring the accuracy and reproducibility of any given diagnostic test carried out is vital in terms of integrating it successfully into clinical practice.
North America & Europe lead the Geographically into Epigenetics Drugs & Diagnostic Technologies Market which has been stimulated by intense research & development activities, well established healthcare infrastructures & high prevalence rates of diseases targeted by epigenomic therapeutics; nonetheless, global expansion is ongoing particularly in Asia-Pacific which is showing increasing interest & promises. These regions are likely experience substantial growth in their markets because both awareness about epigenomics will expand as well as healthcare infrastructure within developing economies steadily improves over time.
Epigenetics Drugs Diagnostic Technologies Market Highlights:
Global Epigenetics Drugs and Diagnostic Technologies Market Overview
The Epigenetics Drugs and Diagnostic Technologies Market size was valued at USD 6.75 billion in 2022 and is projected to grow from USD 8.23 billion in 2023 to USD 48.91 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 21.90% during the forecast period (2023 - 2032).
The growth of the market is driven by factors such as the increasing prevalence of chronic diseases such as Central Nervous System (CNS) diseases and oncology and the rising number of product launches & pipeline products.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Epigenetics Drugs and Diagnostic Technologies Market Trends
- Increasing prevalence of chronic diseases such as CNS diseases and oncology
The increasing incidences of chronic diseases of the central nervous system across the globe are increasing the demand for epigenetic drugs and diagnostic technologies. Epigenetics majorly treat central nervous system diseases, including Alzheimer’s, Huntington’s disease, schizophrenia, autism, and bipolar disorder. Furthermore, these drugs have low toxicity and can be given in combination with other types of drugs for better treatment. As per the World Health Organisation, there were 55 million people diagnosed with dementia globally until March 2023, and more than 60% were living in low- and middle-income (LMIC) countries.
Furthermore, according to the Alzheimer’s Association (US), approximately 6.7 million Americans aged 65 and older living with Alzheimer’s dementia in 2023.
FIGURE 2: AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA, AMERICA, 2023
Additionally, epigenetics has shown great results in treating cancer, and these drugs have the capacity to turn off Deoxyribonucleic Acid (DNA). As per GLOBOCAN 2020, breast cancer accounted for the largest share, followed by lung, colorectum, prostate, stomach, and other cancers.
Moreover, in February 2023, Cardio Diagnostics Holdings, Inc. (US) launched PrecisionCHD, the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (CHD). This artificial intelligence (AI)-driven integrated epigenetic-genetic engine assists physicians in the early detection of CHD.
Therefore, the increasing prevalence of oncology and neurology diseases, the high efficacy of epigenetic drugs to treat these diseases, and AI-driven epigenetic product launches are propelling the market growth.
Epigenetics Drugs and Diagnostic Technologies Market Segment Insights
Epigenetics Drugs and Diagnostic Technologies Drug Type Insights
The market segments of epigenetics drugs and diagnostic technologies, based on drug type, into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others including bromodomain inhibitors, protein methyltransferase inhibitors, and histone acetyltransferases (HAT) inhibitors. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others including zebularine, hydralazine, and procaine, and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others including belinostat, panobinostat, and trichostatin A. The DNA methyltransferases (DNMTs) inhibitors segment dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023–2032. The major driving factor for the segments is that these inhibitors are utilized in combination with chemotherapy and immunotherapy to enhance their effectiveness.
Epigenetics Drugs and Diagnostic Technologies Diagnostic Technologies Insights
The epigenetics drugs and diagnostic technologies market segmentation, based on diagnostic technologies, is segmented into DNA methylation and histone modification analysis and others, including non-coding RNA analysis and epigenomic profiling. The DNA methylation segment dominated the market in 2022, and histone modification analysis is projected to be the fastest-growing segment during the forecast period. The DNA methylation diagnostic tool can classify tumors and assist in early diagnosis. As per the National Academy of Science, the NDA methylation diagnostic tool can differentiate cancerous cells with an accuracy of more than 95%. Furthermore, another major application is to diagnose early diagnose genetic diseases.
FIGURE 2: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Epigenetics Drugs and Diagnostic Technologies Application Insights
On the basis of application, the market of epigenetics drugs and diagnostic technologies segment into oncology, neurology, autoimmune diseases, and others. The oncology segment dominated the market in 2022, and neurology is projected to be the fastest-growing segment during the forecast period. DNA methylation plays an imperative role in diagnosing neurological diseases with precision, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. According to the Parkinson's Foundation, there were approximately 90,000 people diagnosed with Parkinson’s disease in the US in 2022.
Epigenetics Drugs and Diagnostic Technologies End User Insights
The market segmentation of epigenetics drugs and diagnostic technologies is based on end user, hospitals & clinics, diagnostic centers, and others, including academic & research institutes and ambulatory surgical centers. The hospitals & clinics segment dominated the market in 2022, and the diagnostic centers segment is projected to be the fastest-growing segment during the forecast period, i.e., 2022 to 2023. The factors influencing the growth of the end user are the increasing prevalence of chronic diseases such as cancer and neurology, raising awareness, and the wide range of applications of epigenetic diagnostic tools.
Epigenetics Drugs and Diagnostic Technologies Regional Insights
By region, the study segments the market into North America, Europe, Asia-Pacific, and the rest of the world. North America epigenetics drugs and diagnostic technologies market held the largest market share in 2022, due to the rising incidences of chronic diseases and the presence of major and active players including Illumina, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), LISEN lmprinting Diagnostics (US), and Salarius Pharmaceuticals, Inc. (US).
Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
FIGURE 3: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's epigenetics drugs and diagnostic technologies market accounted for the second-largest market share due to the rising prevalence of genetic disorders and the launch of epigenetic tests to detect genetic disorders. In March 2019, the European Commission revealed that there are approximately 5.2 million births in Europe each year, and nearly 2.5% of people are born with congenital anomalies, a type of Down syndrome. Moreover, in April 2019, at the London Health Science Centre, a genome-wide DNA methylation test developed by a Canadian team was launched in European clinical laboratories. Furthermore, the Germany market of epigenetics drugs and diagnostic technologies held the largest market share in 2022, and the UK market of epigenetics drugs and diagnostic technologies is projected to be the fastest-growing market in the Europe region.
The Asia-Pacific epigenetics drugs and diagnostic technologies market is expected to grow at a significant rate from 2023 to 2032, owing to the growing incidence of neurological diseases and increasing collaboration for the development of the drugs. As per the Alzheimer’s Disease International revealed in 2020, there are higher chances of Alzheimer’s in developing countries including China, India, South Asia, and Western Pacific neighbors due to the fastest growth of the geriatric population.
Furthermore, in January 2021, Celleron Therapeutics (UK) partnered with Nuance Biotech Ltd. (China) in order to develop a next-generation epigenetic immune regulator to target histone deacetylase to kill cancer. Additionally, it received approval from the Chinese Center for Drug Evaluation for a clinical trial of an investigational new drug (IND) registrational trial to develop CXD101 in patients suffering from peripheral T-cell lymphoma (PTCL). Moreover, the China market of epigenetics drugs and diagnostic technologies accounted for the largest market share, and the India market of epigenetics drugs and diagnostic technologies is projected to be the fastest-growing market in the Asia-Pacific region.
Epigenetics Drugs and Diagnostic Technologies Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of epigenetics drugs and diagnostic technologies grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the epigenetics drugs and diagnostic technologies industry must offer cost-effective products to expand and survive in an increasingly competitive and rising market environment.
Hologic, Inc. (Hologic) is engaged in manufacturing, developing, and supplying diagnostic products, surgical and medical imaging systems with prominence on women’s health. The company operates through four segments, including medical aesthetics, diagnostics, breast health, GYN surgical, and skeletal health.  The company has strong business presence in North America, Europe, Asia-Pacific, and Rest of the World. Moreover, in January 2021: the company acquired Diagenode Diagnostics (Belgium) for USD 159 million, a European molecular diagnostic company specialized in manufacturing and developing molecular diagnostic assays and epigenetic products.
Key Companies in the market of Epigenetics Drugs and Diagnostic Technologies includes.
- Hologic, Inc. (US)
- Gilead Sciences, Inc. (US)
- Celleron Therapeutics (US)
- Illumina, Inc. (US)
- AstraZeneca PLC (UK)
- LISEN lmprinting Diagnostics (US)
- Salarius Pharmaceuticals, Inc. (US)
- Jubilant Therapeutics (US)
- Oryzon Genomics (Spain)
- Epiaxis Therapeutics (Australia)
- Others
Epigenetics Drugs and Diagnostic Technologies Industry Developments
- January 2021: Celleron Therapeutics (UK) partnered with Nuance Biotech Ltd. (China) in order to develop a next-generation epigenetic immune regulator to target histone deacetylase to kill cancer.
- January 2021: Hologic, Inc. (US) acquired Diagenode Diagnostics (Belgium) for USD 159 million, a European molecular diagnostic company specialized in manufacturing and developing molecular diagnostic assays and epigenetic products.
Epigenetics Drugs and Diagnostic Technologies Market Segmentation
Epigenetics Drugs and Diagnostic Technologies Drug Type Outlook
- DNA Methyltransferases (DNMTs) Inhibitors
- Histone Deacetylases (HDACs) Inhibitors
- Histone Methyltransferase (HMT) inhibitors
- Others
Epigenetics Drugs and Diagnostic Technologies Diagnostic Technologies Outlook
- DNA Methylation
- Histone Modification Analysis
- Others
Epigenetics Drugs and Diagnostic Technologies Application Outlook
- Oncology
- Neurology
- Autoimmune Diseases
- Others
Epigenetics Drugs and Diagnostic Technologies End User Outlook
- Hospitals & Clinics
- Diagnostic Centers
- Others
Epigenetics Drugs and Diagnostic Technologies Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
